“The good thing about that was it was bipartisan … But if not, we’ll continue to work … So we’ll be able to, I think we’ll be able to make the PBM reform and other things in that bill ...

In 2021, the FDA approved a new insulin drug, Semglee, that was interchangeable with a brand-name insulin called Lantus. Lantus cost $292 for a 30-day supply. Drugmaker Viatris launched two ...

The price concessions from the pharmacy come from lower contracted rates that pharmacies must accept in order to participate in the PBM’s pharmacy network. Depending on the way an employer ...

A bipartisan, bicameral group of lawmakers is calling on the Federal Trade Commission (FTC) to vote in favor of releasing an interim staff report on pharmacy benefit managers (PBM). Sens.

The Federal Trade Commission (“FTC”) released its second interim report on Jan. 14, 2025, accusing pharmacy benefit managers (PBMs) of marking up the prices of specialty generic drugs.

Sales grew 12% to $2.17 billion in the first quarter in the U.S. healthcare segment — including 9% growth at VillageMD, despite operating fewer clinics. Specialty pharmacy company Shields Health ...

The FTC’s investigation into PBM practices began in 2022. Last summer, the agency released a scathing interim report on the industry. It detailed how increasing concentration enabled the three ...

But beneath the surface of this public scrutiny lies the biggest threat to the traditional PBM structure, one that signals a quiet shift in the market: changing demands from employers, unions ...

The PBM's 41-page lawsuit says allowing the FTC's case to play out as an administrative proceeding overseen by an administrative law judge "would subvert bedrock constitutional principles of ...